(Total Views: 502)
Posted On: 06/01/2025 10:37:08 AM
Post# of 153832
A Penny Stock To Watch In Challenging Cancer Space
May 28, 2025 11:43 AM6 min read
A Penny Stock To Watch In Challenging Cancer Space
by James Gornick Benzinga Contributor
We have a $2.75 Price Target on CytoDyn (CYDY) in the Next 6 to 12 Months. The stock’s current price is around $0.32.
CytoDyn Inc. is a clinical-stage biotechnology company focused on developing leronlimab, a monoclonal antibody targeting the CCR5 receptor, with applications in HIV, immunology, and oncology.
This report provides a comprehensive overview of CytoDyn's progress with leronlimab in treating metastatic triple-negative breast cancer (mTNBC), including regulatory designations, clinical developments, financial outlook, and competitive positioning.
Click It! Support yourself. And the algorithm.
https://www.benzinga.com/general/biotech/25/0...ncer-space
May 28, 2025 11:43 AM6 min read
A Penny Stock To Watch In Challenging Cancer Space
by James Gornick Benzinga Contributor
We have a $2.75 Price Target on CytoDyn (CYDY) in the Next 6 to 12 Months. The stock’s current price is around $0.32.
CytoDyn Inc. is a clinical-stage biotechnology company focused on developing leronlimab, a monoclonal antibody targeting the CCR5 receptor, with applications in HIV, immunology, and oncology.
This report provides a comprehensive overview of CytoDyn's progress with leronlimab in treating metastatic triple-negative breast cancer (mTNBC), including regulatory designations, clinical developments, financial outlook, and competitive positioning.
Click It! Support yourself. And the algorithm.
https://www.benzinga.com/general/biotech/25/0...ncer-space
(5)
(0)
